UCSC Human Gene Sorter
 
genome assembly search
sort by display output 
#
Name
VisiGene
BLASTP
E-Value
Genome Position
Description
1GH1n/a
n/a
n/a
n/a
3e-107chr17 63,918,021growth hormone 1, transcript variant 1 (from RefSeq NM_000515.5)
2ENSG00000285947n/a
n/a
n/a
n/a
3e-155chr17 63,924,294Plays an important role in growth control. Its major role in  stimulating body growth is to stimulate the liver and other tissues to  secrete IGF-1. It stimulates both the differentiation and proliferation  of myoblasts. It also stimulates amino acid uptake and protein  synthesis in muscle and other tissues. (from UniProt A0A3B3ISS9)
3FCMRn/a
n/a
n/a
n/a
n/achr1 206,912,629Fc mu receptor, transcript variant 1 (from RefSeq NM_005449.5)
4IGHJ4n/a
    
    
     
n/achr14 105,864,237immunoglobulin heavy joining 4 (from HGNC IGHJ4)
5MZB1n/a
n/a
n/a
n/a
n/achr5 139,388,690marginal zone B and B1 cell specific protein (from RefSeq NM_016459.4)
6IGHJ3n/a
    
    
     
n/achr14 105,864,611immunoglobulin heavy joining 3 (from HGNC IGHJ3)
7SASH3n/a
    
    
     
n/achrX 129,787,575SAM and SH3 domain containing 3 (from RefSeq NM_018990.4)
8ENSG00000240143n/a
    
    
     
n/achrX 129,795,978ENSG00000240143 (from geneSymbol)
9MAP4K1n/a
n/a
n/a
n/a
n/achr19 38,602,797mitogen-activated protein kinase kinase kinase kinase 1, transcript variant 1 (from RefSeq NM_001042600.3)
10CCL4n/a
n/a
n/a
n/a
n/achr17 36,104,720C-C motif chemokine ligand 4 (from RefSeq NM_002984.4)
11FGD2n/a
n/a
n/a
n/a
n/achr6 37,017,362FYVE, RhoGEF and PH domain containing 2 (from RefSeq NM_173558.4)
12IRF8n/a
n/a
n/a
n/a
n/achr16 85,910,884interferon regulatory factor 8, transcript variant 2 (from RefSeq NM_002163.4)
13PLCG2n/a
n/a
n/a
n/a
n/achr16 81,870,988phospholipase C gamma 2 (from RefSeq NM_002661.5)
14POU2AF1n/a
n/a
n/a
n/a
n/achr11 111,365,765POU class 2 homeobox associating factor 1 (from RefSeq NM_006235.3)
15ITGB7n/a
n/a
n/a
n/a
n/achr12 53,199,287integrin subunit beta 7, transcript variant 20 (from RefSeq NR_182253.1)
16NAPSBn/a
n/a
n/a
n/a
n/achr19 50,339,319napsin B aspartic peptidase, pseudogene (from HGNC NAPSB)
17ABI3n/a
n/a
n/a
n/a
n/achr17 49,216,966ABI family member 3, transcript variant 1 (from RefSeq NM_016428.3)
18CCR7n/a
    
    
     
n/achr17 40,559,620C-C motif chemokine receptor 7, transcript variant 1 (from RefSeq NM_001838.4)
19MYO1Gn/a
n/a
n/a
n/a
n/achr7 44,970,838myosin IG (from RefSeq NM_033054.3)
20ISG20n/a
n/a
n/a
n/a
n/achr15 88,647,749interferon stimulated exonuclease gene 20, transcript variant 1 (from RefSeq NM_002201.6)
21IGHGPn/a
    
    
     
n/achr14 105,667,238immunoglobulin heavy constant gamma P (non-functional) (from HGNC IGHGP)
22HLA-DOBn/a
n/a
n/a
n/a
n/achr6 32,814,882major histocompatibility complex, class II, DO beta (from RefSeq NM_002120.4)
23MIR142n/a
n/a
n/a
n/a
n/achr17 58,331,275microRNA 142 (from RefSeq NR_029683.1)
24CLEC2Dn/a
n/a
n/a
n/a
n/achr12 9,684,633C-type lectin domain family 2 member D, transcript variant 1 (from RefSeq NM_013269.6)
25NPM1P7n/a
n/a
n/a
n/a
n/achr12 9,695,805nucleophosmin 1 pseudogene 7 (from HGNC NPM1P7)
26ACAP1n/a
n/a
n/a
n/a
n/achr17 7,344,003ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 (from RefSeq NM_014716.4)
27MX1-AS1n/a
n/a
n/a
n/a
n/achr21 41,443,382MX1-AS1 (from geneSymbol)
28LCKn/a
n/a
n/a
n/a
n/achr1 32,268,715LCK proto-oncogene, Src family tyrosine kinase, transcript variant 2 (from RefSeq NM_005356.5)
29PIM2n/a
    
    
     
n/achrX 48,916,103Pim-2 proto-oncogene, serine/threonine kinase (from RefSeq NM_006875.4)
30IL2RBn/a
n/a
n/a
n/a
n/achr22 37,137,879interleukin 2 receptor subunit beta, transcript variant 1 (from RefSeq NM_000878.5)
31CD69n/a
n/a
n/a
n/a
n/achr12 9,756,693CD69 molecule (from RefSeq NM_001781.2)
32RASAL3n/a
n/a
n/a
n/a
n/achr19 15,458,084RAS protein activator like 3, transcript variant 10 (from RefSeq NR_174478.1)
33GPR15n/a
n/a
n/a
n/a
n/achr3 98,533,329G protein-coupled receptor 15 (from RefSeq NM_005290.4)
34CCL3-AS1n/a
n/a
n/a
n/a
n/achr17 36,081,361CCL3-AS1 (from geneSymbol)
35TRACn/a
n/a
n/a
n/a
n/achr14 22,549,831T cell receptor alpha constant (from HGNC TRAC)
36IGHDn/a
n/a
n/a
n/a
n/achr14 105,841,221immunoglobulin heavy constant delta (from HGNC IGHD)
37SLAMF6n/a
n/a
n/a
n/a
n/achr1 160,504,145SLAM family member 6, transcript variant 1 (from RefSeq NM_001184714.2)
38IFI44Ln/a
n/a
n/a
n/a
n/achr1 78,633,296interferon induced protein 44 like, transcript variant 1 (from RefSeq NM_006820.4)
39MX2n/a
n/a
n/a
n/a
n/achr21 41,385,710MX dynamin like GTPase 2 (from RefSeq NM_002463.2)
40HLA-DOAn/a
n/a
n/a
n/a
n/achr6 33,006,886major histocompatibility complex, class II, DO alpha (from RefSeq NM_002119.4)
41IRF5n/a
n/a
n/a
n/a
n/achr7 128,943,982interferon regulatory factor 5, transcript variant 10 (from RefSeq NM_001364314.2)
42DENND1Cn/a
n/a
n/a
n/a
n/achr19 6,474,497DENN domain containing 1C, transcript variant 1 (from RefSeq NM_024898.4)
43APOBEC3Gn/a
n/a
n/a
n/a
n/achr22 39,082,509apolipoprotein B mRNA editing enzyme catalytic subunit 3G, transcript variant 1 (from RefSeq NM_021822.4)
44BCL2A1n/a
    
    
     
n/achr15 79,966,044BCL2 related protein A1, transcript variant 1 (from RefSeq NM_004049.4)
45SLAMF7n/a
n/a
n/a
n/a
n/achr1 160,747,034SLAM family member 7, transcript variant 1 (from RefSeq NM_021181.5)
46LY86n/a
n/a
n/a
n/a
n/achr6 6,621,851lymphocyte antigen 86 (from RefSeq NM_004271.4)
47BLKn/a
n/a
n/a
n/a
n/achr8 11,529,493BLK proto-oncogene, Src family tyrosine kinase, transcript variant 1 (from RefSeq NM_001715.3)
48TBC1D10Cn/a
n/a
n/a
n/a
n/achr11 67,407,086TBC1 domain family member 10C, transcript variant 1 (from RefSeq NM_198517.4)
49NCKAP1Ln/a
n/a
n/a
n/a
n/achr12 54,522,997NCK associated protein 1 like, transcript variant 1 (from RefSeq NM_005337.5)
50IGKV3-15n/a
    
    
     
n/achr2 89,085,482V region of the variable domain of immunoglobulin light  chains that participates in the antigen recognition (PubMed:24600447).  Immunoglobulins, also known as antibodies, are membrane-bound or  secreted glycoproteins produced by B lymphocytes. In the recognition  phase of humoral immunity, the membrane-bound immunoglobulins serve as  receptors which, upon binding of a specific antigen, trigger the clonal  expansion and differentiation of B lymphocytes into immunoglobulins-  secreting plasma cells. Secreted immunoglobulins mediate the effector  phase of humoral immunity, which results in the elimination of bound  antigens (PubMed:20176268, PubMed:22158414). The antigen binding site  is formed by the variable domain of one heavy chain, together with that  of its associated light chain. Thus, each immunoglobulin has two  antigen binding sites with remarkable affinity for a particular  antigen. The variable domains are assembled by a process called V-(D)-J  rearrangement and can then be subjected to somatic hypermutations  which, after exposure to antigen and selection, allow affinity  maturation for a particular antigen (PubMed:20176268, PubMed:17576170). (from UniProt P01624)